Publications by Oncolines Scientists on
Cell Panel Profiling, SynergyFinder™, Mechanistic Cell Biology:

  • Grobben et al. (2023) Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1. Cancers, 15(3):893. (Collaboration with Radboud University Medical Center and Pangaea Oncology)
  • Kooijman et al. (2022) Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Frontiers in Oncology, section Cancer Molecular Targets and Therapeutics, 12:953013.
  • Grobben et al. (2021) Targeting indoleamine 2,3-dioxygenase in cancer models using the novel small molecule inhibitor NTRC 3883-0. Frontiers in Immunology, section Cancer Immunity and Immunotherapy, 11:609490. (Collaboration with Radboud University Medical Center)
  • Conlon et al. (2021) Comparative analysis of drug response and gene profiling of the HER2-targeted tyrosine kinase inhibitors. British Journal of Cancer, 124 (7):1249-1259. (Collaboration with Dublin City University and Puma Biotechnology, Inc.)
  • den Ouden et al. (2020) Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites. Oncotarget, 11:4570-4581. (Collaboration with Radboud University Medical Center)
  • Uitdehaag et al. (2019) Combined cellular and biochemical profiling to identify predictive drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017. Molecular Cancer Therapeutics, 18 (2):470-481.
  • Zaman et al. (2017) TTK inhibitors as a targeted therapy for CTNNB1 (β-catenin) mutant cancers. Molecular Cancer Therapeutics, 16 (11):2609-2617.
  • Libouban et al. (2017) Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines. Oncotarget, 8 (24):38309–38325. (Collaboration with Netherlands Cancer Institute)
  • Uitdehaag et al. (2016) Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors. Molecular Cancer Therapeutics, 15 (12):3097-3109.
  • de Roos JA, Uitdehaag JC, de Man AP, Buijsman RC, Zaman GJR, inventors; Netherlands Translational Research Center B.V., assignee. Prognostic biomarkers for TTK inhibitor chemotherapy. Patent WO 2016/166255 A1. 2016 Oct 20
  • Uitdehaag et al. (2015) Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. PLoS ONE, 10 (5):e0125021.
  • Uitdehaag et al. (2014) Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use. PLoS ONE, 9 (3):e92146.

References by our Clients to Oncolines®, SynergyFinder™, Mechanistic Cell Biology:

  • Gupta et al. (2023) High SLFN11 expression correlates with sensitivity to lurbinectidin in small cell lung cancer (SCLC) models. Poster presentation at AACR Annual Meeting. (Affiliation: Jazz Pharmaceuticals, Inc.)
  • Gorter et al. (2023) Preclinical evaluation of MCLA-129, a bispecific antibody targeting EGFR and c-MET on solid tumor cells, in comparison with amivantama. Poster presentation at AARC Annual Meeting. (Affiliation: Merus N.V.)
  • King et al. (2022) Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles. Poster presentation at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. (Affiliation: University of Edinburgh, Cancer Research U.K., and Nuvectis Pharma Inc.)
  • Hughes et al. (2022) Uncovering the molecular mechanisms which predict sensitivity to a novel SRC kinase inhibitor NXP900 to inform personalized healthcare strategies. Poster presentation at AACR Annual Meeting 2022. (Affiliation: Cancer Research U.K., University of Edinburgh, and Nuvectis Pharma Inc.)
  • Lane et al. (2022) BAL0891: a novel dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division resulting in potent anti-cancer activity. Poster presentation at AACR Annual Meeting 2022. (Affiliation: Basilea Pharmaceutica International Ltd.)
  • Lane et al. (2022) BAL0891: a novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) with potent single agent activity. Poster presentation at ESMO TAT conference 2022. (Affiliation: Basilea Pharmaceutica International Ltd.)
  • Cordo et al. (2022) Phosophoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies. Nature Communications, 13:1048. (Affiliation: Prinses Máxima Center for Pediatric Oncology)
  • van der Zwet et al. (2021) MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance. Leukemia, 35 (12):3394-3405. (Affiliation: Prinses Máxima Center for Pediatric Oncology)
  • Beauchamp et al. (2020) Targeting N-myristoylation for therapy of B-cell lymphomas. Nature Communications, 11:5348. (Affiliations: University of Alberta and Pacylex Pharmaceuticals)
  • Borsari et al. (2019) Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl−Pyrimidine Moiety. ACS Medicinal Chemistry Letters, 10:1473-1479. (Affilitations: University of Basel and PIQUR Therapeutics AG)
  • Rageot et al. (2019) (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. Journal of Medicinal Chemistry, 62 (13):6241-6261. (Affiliations: University of Basel and PIQUR Therapeutics AG)
  • Grünewald et al. (2019) Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models. International Journal of Cancer, 145 (5): 346-1357. (Affiliation: Bayer AG)
  • Gentile et al. (2018) A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study. Pharmaceuticals, 11 (1):22. (Affiliation: University of Alberta)
  • Bohnacker et al. (2017) Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. Nature Communications, 8:14683. (Affiliation: University of Basel)
  • Politz et al. (2017) Preclinical activity of the FGFR inhibitor rogaratinib (BAY 1163877) alone or in combination with antihormonal therapy in breast cancer. Cancer Research, 77 (13 Supplement):1079. (Affiliation: Bayer AG)
  • Li et al. (2016) IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study. PLoS Med, 13 (12):e1002200. (Affiliations: Erasmus MC and NTRC)
  • Canté-Barrett et al. (2016) MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. Leukemia, 30:1832-1843. (Affiliations: Erasmus MC and NTRC)
  • Maia et al. (2015) Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. Annals of Oncology, 26 (10):2180-2192. (Affiliations: Netherlands Cancer Institute and NTRC)
  • Cmiljanovic et al. (2015) PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor, Cancer Research, 75 (15 Supplement):2664-2664. (Affiliation: PIQUR Therapeutics AG)
  • Hudlebusch et al. (2014) The development of therapeutic inhibitors of the KDM5 histone demethylases, Cancer Research, 74 (19 Supplement): 5161-5161. (Affiliation: EpiTherapeutics)